The purpose of this study is to investigate the efficacy of intravenous lidocaine on THBS2, MMPs and VEGF-C in serum in cervical cancer patients undergoing radical hysterectomy under general anesthesia.
The surgical stress response to tumour removal causes bloodstream release of a variety of pro-inflammatory cytokines and other molecules which may affect perioperative immune response and other conditions conducive to residual tumour cell survival that could later emerge as clinical recurrences or metastasis. Lidocaine has analgesic and anti-inflammatory effects, and may also have specific anticancer properties. Blood serum expression of these molecules (metalloproteinases, vascular endothelial growth factor \[VEGF\], epidermal growth factor）, play a important role in the metastatic process and tumor progression. lidocaine could affect the course and growth of metastatic tumors by changing the cancer cells, the tumor microenvironment, or both. We tested the hypothesis that women undergoing cervical cancer resection with these techniques (intravenous lidocaine) have reduced postoperative serum expression of metastasis biomarkers, and may change the outcomes of cancer patients.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Enrollment
60
Intravenous bolus of 1.5 mg/kg of lidocaine followed by a continuous infusion of 3.0 mg/kg for the frst hour, 1.5 mg/kg for the second hour, 0.7 mg/kg for the next 22h.
Patients are received equal volumes of saline intravenously until the end of the surgery
Changes from Baseline THBS2 before anaesthetic induction and 48 hours after surgery
Blood samples (5 ml) were drawn from each patient before anaesthetic induction, at the end of the operation, 24h and 48 h after operation
Time frame: Baseline and 48 hours after operation
Changes from Baseline MMP-2 before anaesthetic induction and 48 hours after surgery
Blood samples (5 ml) were drawn from each patient before anaesthetic induction, at the end of the operation, 24h and 48 h after operation
Time frame: Baseline and 48 hours after operation
Changes from Baseline MMP-9 before anaesthetic induction and 48 hours after surgery
Blood samples (5 ml) were drawn from each patient before anaesthetic induction, at the end of the operation, 24h and 48 h after operation
Time frame: Baseline and 48 hours after operation
Changes from Baseline VEGF-C before anaesthetic induction and 48 hours after surgery
Blood samples (5 ml) were drawn from each patient before anaesthetic induction, at the end of the operation, 24h and 48 h after operation
Time frame: Baseline and 48 hours after operation
Monitoring the severity of postoperative pain with verbalre sponse pain score during the first 48hours postoperatively
the severity of pain measured using Visual Analogue Score (VAS) on postoperative days at the moment, 12, 24 and 48 hours after surgery
Time frame: at the end of operation and 48 hours after operation
Resumption of bowel function
Record the time to first flatus and the first defecation
Time frame: at the end of operation and 48 hours after operation
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.